Our Science
Our Science
Cutting-edge research and technology
Our initiatives
Our initiatives
Campaigning for a smoke-free future
Smoke-Free Life
Smoke-Free Life
Go beyond your past, make a positive change

Why invest in PMI?

We've built the world's most successful cigarette company. Now we're building our future on smoke-free products that are much better choices.

$ 7568

0.00 (0%)

Investor Relations

Latest Press Releases

Media Center
  • Press Release 23 Mar, 2020

    Philip Morris International Inc. Announces Temporary Suspension of Operations at Manufacturing Technology Bologna

  • News 19 Mar, 2020

    Medicago develops a plant-based vaccine for Coronavirus

  • Press Release 13 Mar, 2020

    Philip Morris International Demonstrates Commitment to Developing an Inclusive and Diverse Workplace with Appointment of Silke Muenster, Chief Diversity Officer

  • News 10 Mar, 2020

    Using certifications for drive progress on gender balance: Observations from PMI’s global EQUAL-SALARY certification

This site is operated for the purpose of providing general information about us. The site is not operated for advertising or marketing purposes. The material on this site should not be regarded as an offer to sell, or a solicitation of an offer to buy, any product of PMI. Such products are sold only in compliance with the laws of the particular jurisdictions in which they are sold. PMI has now been granted authorization to market IQOS 2.4 in the U.S. from the Food and Drug Administration (FDA), which Altria will bring to the U.S. market under the terms of a license from PMI. The FDA has not yet determined whether IQOS 2.4 meets the standard to be marketed in the U.S. as a modified risk tobacco product. PMI’s applications to the FDA seeking authorization to market IQOS in the U.S. as a modified risk product are currently under review.